Nicardipine HClCAS# 54527-84-3 |
- Sulfo-NHS-Biotin
Catalog No.:BCC3576
CAS No.:119616-38-5
- Sulfo-NHS-LC-Biotin
Catalog No.:BCC3578
CAS No.:127062-22-0
- NHS-Biotin
Catalog No.:BCC3577
CAS No.:35013-72-0
- Biotin Hydrazide
Catalog No.:BCC3582
CAS No.:66640-86-6
- NHS-LC-Biotin
Catalog No.:BCC3579
CAS No.:72040-63-2
- Iodoacetyl-LC-Biotin
Catalog No.:BCC3584
CAS No.:93285-75-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 54527-84-3 | SDF | Download SDF |
| PubChem ID | 41114 | Appearance | Powder |
| Formula | C26H30ClN3O6 | M.Wt | 515.99 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | YC-93 Hydrochloride | ||
| Solubility | DMSO : ≥ 35 mg/mL (67.83 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride | ||
| SMILES | [H+].[Cl-].COC(=O)C1=C(C)NC(=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OCCN(C)Cc3ccccc3)C | ||
| Standard InChIKey | AIKVCUNQWYTVTO-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C26H29N3O6.ClH/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19;/h5-12,15,24,27H,13-14,16H2,1-4H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Nicardipine Hcl(YC-93) is a calcium channel blocker that has been widely used to control blood pressure in severe hypertension following events such as ischemic stroke, traumatic brain injury, and intracerebral hemorrhage. References: | |||||
Nicardipine HCl Dilution Calculator
Nicardipine HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.938 mL | 9.6901 mL | 19.3802 mL | 38.7604 mL | 48.4506 mL |
| 5 mM | 0.3876 mL | 1.938 mL | 3.876 mL | 7.7521 mL | 9.6901 mL |
| 10 mM | 0.1938 mL | 0.969 mL | 1.938 mL | 3.876 mL | 4.8451 mL |
| 50 mM | 0.0388 mL | 0.1938 mL | 0.3876 mL | 0.7752 mL | 0.969 mL |
| 100 mM | 0.0194 mL | 0.0969 mL | 0.1938 mL | 0.3876 mL | 0.4845 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders.
- Methyl protogracillin
Catalog No.:BCN8177
CAS No.:54522-53-1
- Methyl protodioscin
Catalog No.:BCN6342
CAS No.:54522-52-0
- H-Leu-CMK.HCl
Catalog No.:BCC2971
CAS No.:54518-92-2
- 5-Aminolevulinic acid HCl
Catalog No.:BCC4883
CAS No.:5451-09-2
- Erythrodiol
Catalog No.:BCN5726
CAS No.:545-48-2
- Lupeol
Catalog No.:BCN5725
CAS No.:545-47-1
- Uvaol
Catalog No.:BCN5724
CAS No.:545-46-0
- 5-Glutinen-3-ol
Catalog No.:BCN5723
CAS No.:545-24-4
- Jolkinolide E
Catalog No.:BCN3772
CAS No.:54494-34-7
- 3alpha-dihydrocadambine
Catalog No.:BCN8151
CAS No.:54483-84-0
- JNJ 10181457 dihydrochloride
Catalog No.:BCC7842
CAS No.:544707-20-2
- UBP 282
Catalog No.:BCC7171
CAS No.:544697-47-4
- QNZ (EVP4593)
Catalog No.:BCC2249
CAS No.:545380-34-5
- AMG 9810
Catalog No.:BCC7329
CAS No.:545395-94-6
- Quercetin-3-O-glucose-6'-acetate
Catalog No.:BCN6545
CAS No.:54542-51-7
- Doxercalciferol
Catalog No.:BCC4902
CAS No.:54573-75-0
- Conessine
Catalog No.:BCC7352
CAS No.:546-06-5
- Alantolactone
Catalog No.:BCN1033
CAS No.:546-43-0
- α-Thujone
Catalog No.:BCC8271
CAS No.:546-80-5
- Columbin
Catalog No.:BCN2622
CAS No.:546-97-4
- Boc-Lys(2-Cl-Z)-OH
Catalog No.:BCC3416
CAS No.:54613-99-9
- URB597
Catalog No.:BCC2324
CAS No.:546141-08-6
- Diethyl 2-acetamido-2-phenethylmalonate
Catalog No.:BCC8940
CAS No.:5463-92-3
- Boc-Hyp(Bzl)-OH.DCHA
Catalog No.:BCC3253
CAS No.:54631-81-1
Formulation and investigation of nicardipine HCl-alginate gel beads with factorial design-based studies.[Pubmed:9795073]
Eur J Pharm Sci. 1998 Jul;6(3):241-6.
The release rate of Nicardipine HCl from various alginate gel bead formulations was investigated. The formulations were prepared by utilizing 23 factorial design. The effect of drug:polymer weight ratio, CaCl2 and sodium-alginate concentration on the time for 50% of the drug to be released (t50%) and the drug entrapment efficiency were evaluated with analysis of variance. The mean particle size and the swelling ratio of the beads were determined. The in vitro release studies were carried out by flow-through cell apparatus in different media (pH 1.2, 2.5, 4.5, 7 and 7.5 buffer solutions). Drug:polymer weight ratio and the interaction of drug:polymer weight ratio and CaCl2 concentration had a significant effect on the drug entrapment efficiency. The release of nicardipine was extended with the alginate gel beads, which were prepared in a ratio of 1:1 (drug:polymer). The release of drug from alginate gel beads took place both by diffusion through the swollen matrix and relaxation of the polymer at pH 1.2-4.5. However, the release was due to the diffusion and erosion mechanism at pH 7-7.5.
Use of a calcium channel blocker (nicardipine HCl) in the treatment of childhood moyamoya disease.[Pubmed:7822727]
J Child Neurol. 1994 Oct;9(4):378-80.
Moyamoya disease is a cerebrovascular disease characterized radiologically by progressive narrowing and occlusion of the arteries contributing to the circle of Willis and its branches. There is formation of an exuberant collateral network of blood vessels at the base of the brain, which is thought to arise in response to chronic ischemia. Clinically, the course is variable, with patients having repeated transient ischemic attacks, strokes, migraine, and seizures. Effective treatment is not available. The etiology and pathophysiology of moyamoya disease are largely unknown. Two patients with arteriographically proven moyamoya disease were identified. Both patients were symptomatic before age 5 years. Despite successful encephaloduroarteriosynangiosis revascularization procedures, they continued to experience an inexorable downhill course. A calcium channel blocker (Nicardipine HCl) was introduced in order to prevent further symptoms. After the introduction of nicardipine, no further strokes occurred in either patient. There were no further episodes of transient ischemic attacks, seizures, or headache in one patient and decreased frequency in the other. In patients with moyamoya disease, nicardipine may have a beneficial effect on cerebral hemodynamics and may prevent ischemic sequelae by optimizing existing collateral circulation.
Preliminary bioequivalence testing of two nicardipine HCl sustained-release formulations with in vitro/in vivo correlations.[Pubmed:11554424]
Eur J Drug Metab Pharmacokinet. 2001 Jan-Jun;26(1-2):1-7.
A new Nicardipine HCl oral sustained-release dosage form was evaluated for bioequivalence in comparison with a reference product, Cardene SR. Six healthy subjects, fasted overnight, were enrolled in a single-dose, open-label, randomized, and two-way crossover study. Blood samples were collected over a 12 hour period, and nicardipine plasma concentrations analyzed from plasma. Pharmacokinetic parameters, including Cmax, t(max), and AUC, were obtained from drug plasma concentration-time curves and pharmacokinetic analysis conducted using WinNonlin. The two one-sided t-test was applied in statistical analysis for comparison of the pharmacokinetic parameters between the two products. There was no convincing evidence that Nicardipine HCl test product and Cardene SR were bioequivalent. Amounts of Nicardipine HCl release in vivo was mathematically obtained by deconvoluting plasma concentration-time data after oral administration using IV bolus injection data as a reference. Plots of percentages of drug release in vitro against those in vivo illustrated triphasic curves. After the in vitro time scale was corrected and then plotted against in vivo data, plots provided a polynomial relationship (R2 of 0.9920 and 0.9954). The in vitro/in vivo correlation may be useful in reformulating this particular test formulation to obtain a product with an in vivo release rate identical to Cardene SR.
Right ventricular performance during hypotension induced by prostaglandin E1, nicardipine HCl, glycerine trinitrate, and isosorbide dinitrate.[Pubmed:23839680]
J Anesth. 1997 Jun;11(2):105-10.
This study investigated right ventricular (RV) performance during hypotensive anesthesia and compared the effect of the vasodilators prostaglandin E1 (PGE1), Nicardipine HCl (Nic), glycerin trinitrate (GTN), and isosorbide dinitrate (ISDN) on RV function. Fifty patients were allocated into four groups [PGE1 (n=20), Nic (n=10), GTN (n=10), and ISDN (n=10)] in random order. Pulmonary and RV hemodynamics were measured using a rapid-response thermodilution catheter before and during induced hypotension, when systolic arterial pressure was maintained at 80 mmHg. In the PGE1, GTN, and ISDN groups, RV end-diastolic volume (RVEDV) and pulmonary vascular resistance were reduced in a similar manner. However, RV ejection fraction increased only in the PGE1 group, and as a consequence, RV stroke volume (RVSV) was maintained. Nic did not change the RV parameters observed, but reduced only systemic vascular resistance (SVR). PGE1 enhanced RV function during induced hypotension. Nic was a useful alternative agent for hypotensive anesthesia. GTN and ISDN reduced RV preload and RVSV; however, cardiac output was maintained by increasing heart rate (HR). Therefore, such nitrates should be used under an adequate RV preload.
